Clinical Trial Detail

NCT ID NCT02718066
Title Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors HUYA Bioscience International
Indications

lung non-small cell carcinoma

melanoma

renal cell carcinoma

Therapies

Chidamide + Nivolumab

Age Groups: adult senior

No variant requirements are available.